Pendetide HCl | CAS# 159489-28-8 (HCl) | chelating agent

MedKoo Cat#: 414845 | Name: Pendetide HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Pendetide HCl is a chelating agent. It consists of pentetic acid linked to the tripeptide glycine – L-tyrosine – L-lysine.

Chemical Structure

Pendetide HCl

CAS#159489-28-8 (HCl)

Theoretical Analysis

MedKoo Cat#: 414845

Name: Pendetide HCl

CAS#: 159489-28-8 (HCl)

Chemical Formula: C31H48ClN7O14

Exact Mass:

Molecular Weight: 778.21

Elemental Analysis: C, 47.85; H, 6.22; Cl, 4.56; N, 12.60; O, 28.78

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

159489-28-8 (HCl); 148805-91-8 (free base)

Synonym

Pendetide hydrochloride; Pendetide HCl

IUPAC/Chemical Name

(S)-17-((S)-2-(2-aminoacetamido)-3-(4-hydroxyphenyl)propanamido)-3,6,9-tris(carboxymethyl)-11-oxo-3,6,9,12-tetraazaoctadecanedioic acid hydrochloride

InChi Key

JMNLEUSKHHGBMQ-SJEIDVEUSA-N

InChi Code

InChI=1S/C31H47N7O14.ClH/c32-14-24(40)34-23(13-20-4-6-21(39)7-5-20)30(50)35-22(31(51)52)3-1-2-8-33-25(41)15-37(17-27(44)45)11-9-36(16-26(42)43)10-12-38(18-28(46)47)19-29(48)49;/h4-7,22-23,39H,1-3,8-19,32H2,(H,33,41)(H,34,40)(H,35,50)(H,42,43)(H,44,45)(H,46,47)(H,48,49)(H,51,52);1H/t22-,23-;/m0./s1

SMILES Code

NCC(N[C@H](C(N[C@H](C(O)=O)CCCCNC(CN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC(O)=O)=O)=O)Cc1ccc(O)cc1)=O.Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 778.21 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Leung K. 111In-Capromab pendetide. 2005 Oct 5 [updated 2008 May 24]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 20641439. 2: Haseman MK, Rosenthal SA, Polascik TJ. Capromab Pendetide imaging of prostate cancer. Cancer Biother Radiopharm. 2000 Apr;15(2):131-40. doi: 10.1089/cbr.2000.15.131. PMID: 10803318. 3: Lamb HM, Faulds D. Capromab pendetide. A review of its use as an imaging agent in prostate cancer. Drugs Aging. 1998 Apr;12(4):293-304. doi: 10.2165/00002512-199812040-00004. PMID: 9571393. 4: Rosenthal SA, Haseman MK, Polascik TJ. Utility of capromab pendetide (ProstaScint) imaging in the management of prostate cancer. Tech Urol. 2001 Mar;7(1):27-37. PMID: 11272670. 5: Manyak MJ. Indium-111 capromab pendetide in the management of recurrent prostate cancer. Expert Rev Anticancer Ther. 2008 Feb;8(2):175-81. doi: 10.1586/14737140.8.2.175. PMID: 18279057. 6: Sodee DB, Nelson AD, Faulhaber PF, Maclennan GT, Resnick MI, Bakale G. Update on fused capromab pendetide imaging of prostate cancer. Clin Prostate Cancer. 2005 Mar;3(4):230-8. doi: 10.3816/cgc.2005.n.004. PMID: 15882479. 7: Hardie AD, Rieter WJ, Bradshaw ML, Gordon LL, Young MA, Keane TE. Improved performance of SPECT-CT In-111 capromab pendetide by correlation with diffusion- weighted magnetic resonance imaging for identifying metastatic pelvic lymphadenopathy in prostate cancer. World J Urol. 2013 Dec;31(6):1327-32. doi: 10.1007/s00345-013-1079-2. Epub 2013 Apr 18. PMID: 23595605. 8: Leung K. N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine. 2008 Nov 1 [updated 2008 Dec 2]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 20641595. 9: Chopra A. N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-S< /i>-[11C]methyl-L-cysteine. 2007 Mar 1 [updated 2007 Dec 6]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 20641248. 10: Schuster DM, Savir-Baruch B, Nieh PT, Master VA, Halkar RK, Rossi PJ, Lewis MM, Nye JA, Yu W, Bowman FD, Goodman MM. Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT. Radiology. 2011 Jun;259(3):852-61. doi: 10.1148/radiol.11102023. Epub 2011 Apr 14. PMID: 21493787; PMCID: PMC3099047.